Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Endosc. Feb 10, 2016; 8(3): 128-142
Published online Feb 10, 2016. doi: 10.4253/wjge.v8.i3.128
Published online Feb 10, 2016. doi: 10.4253/wjge.v8.i3.128
Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy
Domenico Viterbo, Tamas Gonda, Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, NY 10032, United States
Valerie Gausman, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, United States
Author contributions: Viterbo D, Gausman V and Gonda T contributed to the literature search, drafting of the manuscript, proof-reading and approval of the final version for submission; Viterbo D and Gausman V contributed equally to this work.
Conflict-of-interest statement: All authors declare that we have no conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Tamas Gonda, MD, Assistant Professor of Medicine, Division of Digestive and Liver Diseases, Columbia University Medical Center, 161 Fort Washington Avenue, Suite 862, New York, NY 10032, United States. tg2214@cumc.columbia.edu
Telephone: +1-212-3051909 Fax: +1-212-3051081
Received: July 29, 2015
Peer-review started: July 29, 2015
First decision: October 13, 2015
Revised: October 17, 2015
Accepted: December 7, 2015
Article in press: December 8, 2015
Published online: February 10, 2016
Processing time: 186 Days and 6.4 Hours
Peer-review started: July 29, 2015
First decision: October 13, 2015
Revised: October 17, 2015
Accepted: December 7, 2015
Article in press: December 8, 2015
Published online: February 10, 2016
Processing time: 186 Days and 6.4 Hours
Core Tip
Core tip: The poor prognoses of pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CCA) are strongly related to lack of effective screening modalities as well as few therapeutic options. Several novel biomarkers have been studied that have shown promise for early diagnosis and targeted therapy of these malignancies. These biomarkers provide a strong background for future clinical studies to screen for PDAC and CCA in the general population as well as to investigate molecularly targeted therapies.